Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Medicago Licenses China Rights for Flu Vaccine to Phillip Morris Co.

publication date: Sep 26, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Medicago, a Canadian vaccines company, has out-licensed China rights to its pandemic and seasonal flu vaccines to Philip Morris Products, the cigarette maker, in a $12 million deal. PMP has owned a 40% stake in Medicago since 2008. In addition, Medicago signed an exclusive license for a portfolio of plant-based protein development technologies from PMP. The technology will allow Medicago to grow its vaccines on tobacco plants, a faster, less-expensive production method than the methods currently in use. More details...

Stock Symbol: (TSX: MDG)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners